To generate reagents against AZM-152, a drug candidate from TDB azome project.
Ended Purchase Order Awarded Last action
- Contract number
- 75N95C25P00114
- Awardee
-
A&G Pharmaceutical, Inc. UEI SN6SWFABJXL1
- Awarding agency
-
National Center for Advancing Translational Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $13,600
Award facts
- Contract value 100% obligated
- $13,600.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325998 All Other Miscellaneous Chemical Product and Preparation Manufacturing
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Columbia, MD 21045, USA
Award details come from SAM.gov/FPDS.
About this award
The National Center for Advancing Translational Sciences (NCATS) awarded a $13.6K firm fixed-price purchase order to A&G Pharmaceutical, Inc. on September 24, 2025, for the generation of reagents against AZM-152, a drug candidate from the TDB AZOME project. The contract, which will be completed by September 23, 2026, was awarded without set-aside designation through open competition. Work will be performed at A&G Pharmaceutical's facility in Columbia, Maryland.
A&G Pharmaceutical, doing business as Precision Antibody, is a specialized manufacturer of biological research materials and custom antibody development services based in Columbia, Maryland, with over two decades of federal contracting experience. The company maintains a $100 million blanket purchase agreement with the National Institutes of Health Office of Logistics and Acquisition Operations and has established a track record of supporting federal biomedical research initiatives across diverse therapeutic areas including oncology, infectious disease, and neurodegenerative disease research. This award supports NCATS's translational science mission by enabling the development of critical research reagents needed for the advancement of the AZM-152 drug candidate through the development pipeline.
Quick answers
Who was awarded contract 75N95C25P00114?
75N95C25P00114 was awarded to A&G Pharmaceutical, Inc. by National Center for Advancing Translational Sciences (National Institutes of Health) on September 24, 2025.
How much is contract 75N95C25P00114 worth?
The government has obligated $13,600 on 75N95C25P00114.
Was contract 75N95C25P00114 competed?
The extent of competition for 75N95C25P00114 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award